Abstract
e22115 Background: GI cancers account for about 20% of all cancers diagnosed in the US. Therapeutic options in relapsed/refractory disease are limited and the outcomes are poor. Advanced therapeuti...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have